Cat.No. | Name | Information |
---|---|---|
M5160 | Reparixin | Reparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors with IC50 of 1 and 100 nM, respectively. |
M3887 | SB225002 | SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM and >150-fold selectivity over CXCR1 and four other 7-TMRs. |
M1898 | Plerixafor (AMD3100) | Plerixafor (AMD3100) is a CXCR4 chemokine receptor antagonist. |
M43834 | AMD 070 hydrochloride | AMD 070 hydrochloride is a selective, orally active chemokine receptor (CXCR4) antagonist with an IC50 value of 13 nM. |
M31026 | Balixafortide TFA | Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects. |
M27720 | Balixafortide | Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects. |
M21310 | ACT-1004-1239 | ACT-1004-1239 is a potent, selective, orally administered CXCR7 antagonist with an IC50 value of 3.2 nM. |
M13947 | UNBS5162 | UNBS5162 is a pan-antagonist of CXCL chemokine expression, with anti-tumor activity. |
M13946 | SCH 563705 | SCH 563705 is a potent and orally available CXCR2 and CXCR1 antagonist, with IC50s of 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively. |
M13945 | SCH 546738 | SCH 546738 is a potent, orally active and non-competitive CXCR3 antagonist, the affinity constant (Ki) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments. |
M13940 | CXCR2-IN-1 | CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonist with a pIC50 of 9.3. |
M13939 | Mavorixafor trihydrochloride | Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. |
M10230 | LY2510924 | LY2510924 is a potent and selective CXCR4 antagonist, which blocks SDF-1 binding to CXCR4 with IC50 of 0.079 nM. |
M10215 | Motixafortide (BL-8040) | Motixafortide (BL-8040, BKT140) is a synthetic cyclic peptide consisting of 14 amino acids and is an antagonist of CXCR4 with an IC50 value of approximately 1 nM.Motixafortide (BL-8040) is an antagonist of CXCR4 with an IC50 value of approximately 1 nM. |
M10141 | ATI-2341 TFA | ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4). |
M9821 | SX-682 | SX-682 is a potent and selective CXCR1/2 allosteric inhibitor, it may be useful for castration-resistant prostate cancer. |
M9751 | VUF11207 fumarate | VUF11207 fumarate is a CXCR7 agonist and a high-potency CXCR7 ligand (pKi=8.1). |
M9653 | JMS-17-2 | JMS-17-2 is a potent and selective CX3CR1 antagonist with IC50 of 0.32 nM. |
M9288 | MSX-130 | MSX-130 is CXCR4 Antagonist. |
M9286 | MSX-127 | MSX-127 (NSC-23026) is a CXCR4 receptor modulator. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.